Customer Publication
Enter cell line, author or any other phrase or word you would like to search for and click .
![](https://www.tandfonline.com/na101/home/literatum/publisher/tandf/journals/content/dott20/2018/dott20.v011.i00/ott.s163535/20221213/images/medium/dott_a_163535_f0005_c.jpg)
CAT3, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression
Journal: OncoTargets and Therapy (2022)
Research Areas: Cancer research
Cell Lines: T98G, U251 (Giloma cells)
Summary: Glioblastoma multiforme (GBM) is a malignant high-grade glioma with a poor clinical outcome. Temozolomide (TMZ) is the first-line GBM chemotherapy, yet patients commonly develop resistance to it. Therefore, the authors investigated the antitumor activity of CAT3 in TMZ-resistant glioblastoma cell lines U251/TMZ and T98G and demonstrated that CAT3 exhibited antitumor activity via blockade of the Hedgehog pathway and enhanced TMZ cytotoxicity in TMZ-resistant GBM.HoloMonitor M4 was used to measure the growth speed of two different TMZ-resistant glioblastoma cells.